版本:
中国

BRIEF-Abbvie says investigational regimen of Glecaprevir/Pibrentasvir achieved 99 pct SVR(12) rate in chronic hepatitis C patients

April 20 Abbvie Inc

* Abbvie's investigational, pan-genotypic, ribavirin-free regimen of Glecaprevir/Pibrentasvir (G/P) achieved 99 percent SVR(12) rate in chronic hepatitis C patients with compensated cirrhosis

* Abbvie Inc - in expedition-1 study, majority of adverse events were mild and no patients discontinued treatment due to an AE

* Abbvie Inc - most common adverse events (≥10 percent) were fatigue and headache Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐